{"entity":{"id":"nct06216301","kind":"trial","name":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC","aka":[],"tldr":"A phase 3 trial of Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by NovoCure GmbH, now recruiting.","summary":"LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC is a phase 3 interventional study registered as NCT06216301 by NovoCure GmbH, with 734 participants planned, started 2024-07-31 and due to reach its primary completion in 2028-10. Interventions recorded: NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy. Conditions listed: Metastatic Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06216301","url":"https://clinicaltrials.gov/study/NCT06216301"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":["novocure"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06216301","phase":"3","setting":"LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer","sponsor":"NovoCure GmbH","enrolled":734,"outcomes":[]},"route":"/trials/nct06216301/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"novocure","kind":"company","name":"Novocure","route":"/companies/novocure/"}]}}